Importantly, plasma cMLC-1 levels are correlated with disease progression; it is higher in metastatic (n=52) than in non-metastatic (n=27) breast cancer patients (75.96 ± 59.85 ng/mL vs. 43.41 ± 34.26 ng/mL, p=0.0072) (Figure 4A). This evidence concerns the gene MYL3 and breast cancer.